I care for hospitalized patients at the Veterans Administration hospital, and the hospital is the site of my clinical teaching.
I teach medical students in lecture settings and small group sessions in their first and second years, including courses in lung respiration, musculoskeletal, renal and microbiology-immunology. We intermittently have students in our lab and participate in a grant designed to encourage medical students to become physician-scientists.
Residents attend my grand rounds; I also teach fellows in all aspects of their training and mentor those who perform their research projects in my lab.
I have an active, nationally funded translational research program. My research focuses on bacteria called Gram-negative bacilli (GNB) including Escherichia coli, Acinetobacter baumannii and a new hypervirulent variant of Klebsiella pneumoniae.
These GNB cause infection in nearly every non-intestinal site in the body. The hypervirulent variant of K. pneumoniae is both fascinating and worrisome. Unlike its predecessors, it is capable of causing infection in young, healthy hosts and spreading nearly anywhere in the body from the initial infected site, including the eyes and brain. GNB-caused infections result in the loss of billions of health care dollars, millions of work days, and hundreds of thousands of lives each year.
GNB are becoming increasingly resistant to antibiotics, including strains that have become resistant to all available antibiotics. Unfortunately, there are virtually no new antimicrobial agents active against highly resistant GNB in the pharmaceutical “pipeline”. To address this formidable clinical challenge, we have increased our understanding of the bacterial factors that are critical for these GNB to cause infection. We are using this information to develop vaccines for the prevention of infection and antibodies that can be used to treat infection. Other studies involve identifying potential bacterial drug targets; this information will be used to develop new classes of antibiotics.
I work with a number of UB collaborators, including Dr. Campagnari (Microbiology) and Drs. Umland and Schultz (Structural Biology/ Hauptman-Woodward Medical Research Institute).
Education and Training:
Fellowship, Infectious Disease, Tufts-New England Medical Center (1988)
Residency, Medicine, Harvard-New England Deaconess Hospital (1985)
MD, CM, McGill University (1982)
Employment:
Vice Chair of Business Operations, Department of Medicine, University at Buffalo
Professor, University at Buffalo
Senior Staff Fellow, Laboratory of Clinical Investigation, National Institutes of Health, National Institute of Allergy and Infectious Diseases (1989–1994)
Clinical Assistant Instructor, Division of Geographic Medicine and Infectious Diseases, Tufts University (1988–1989)
Awards and Honors:
University at Buffalo Exceptional Scholar Sustained Achievement Award (2012)
Visionary Inventor: UB technology licensed to Zeptometrix Corp. (2009)
Top 100 Principal Investigators at the University at Buffalo (2005)
SUNY Inventor award (for U.S. patent # patent 6,410,703) (2003)
Top 100 Federal Grantees at the University at Buffalo (2002)
F. Carter Pannill Award (1997)
IDSA-Stuart Pharmaceutical Fellowship in Infectious Diseases (1987)
Hinton Book Award-Residency-Harvard-NE Deaconess Hospital (1985)
James McGill Award-McGill University (1981)
James McGill Award-McGill University (1980)
Faculty Scholar-McGill University (1980)
University Scholar-McGill University (1979)
Research Expertise:
Acinetobacter baumannii pathogenesis
Actinomycosis: infections caused by the genera Actinomyces
Bisphosphonate-induced osteonecrosis
Enteric gram-negative bacilli: Infections caused by Gram-negative bacilli
Extraintestinal pathogenic Escherichia coli pathogenesis: pathogenesis
vaccine development
Host-pathogen interactions: Understanding mechanisms by which extraintestinal patghogenic E. coli modify host defenses
Identification of antimicrobial targets
Klebsiella pneumoniae pathogenesis: drug target identification
pathogenesis
biofilms
Microbial pathogenesis: Understanding the mechanisms by which extraintestinal pathogenic E. coli, Acinetobacter, and Klebsiella cause disease
Pathogenesis of urinary tract infection
Vaccine development: Extraintestinal pathogenic E. coli,
Klebsiella pneumoniae, and
Acinetobacter
Grants and Sponsored Research:
April 2011–March 2015 Analysis of A. baumannii capsule as a vaccine candidate Veterans Administration Role: Principal Investigator $604,476
September 2011–October 2014 Identification of New Drug Targets in Multi-Drug Resistant Bacterial Infections Department of Defense (DOD) Role: Co-Principal Investigator $1,744,854
August 2011–July 2013 Identification of genes essential for survival of hypervirulent Kleb. pneumonia NIH Role: Principal Investigator $435,875
March 2007–April 2012 Pathogenesis of Aspiration Pneumonitis NIH Role: Co-Investigator $1,981,250
Patents:
Identification of a vaccine candidate from an extraintestinal isolate of E A potential vaccine candidate or diagnostic tool for infections due to extraintestinal pathogenic E. coli
Manderscheid PA, Bodkin RP, Davidson BA, Jensen E, Russo TA, Knight PR. Bacterial clearance and cytokine profiles in a murine model of postsurgical nosocomial pneumonia.. Clin Diagn Lab Immunol. 2004; 11(4).
Rotta AT, Shiley KT, Davidson BA, Helinski JD, Russo TA, Knight PR. Gastric acid and particulate aspiration injury inhibits pulmonary bacterial clearance.. Crit Care Med. 2004; 32(3).
Johnson JR, Gajewski A, Lesse AJ, Russo TA. Extraintestinal pathogenic Escherichia coli as a cause of invasive nonurinary infections.. J Clin Microbiol. 2003; 41(12).
Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.. Infect Immun. 2003; 71(12).
Russo TA, Davidson BA, Topolnycky DM, Olson R, Morrill SA, Knight PR, Murphy PM. Human neutrophil chemotaxis is modulated by capsule and O antigen from an extraintestinal pathogenic Escherichia coli strain.. Infect Immun. 2003; 71(11).
Russo TA, Davidson BA, Carlino-MacDonald UB, Helinski JD, Priore RL, Knight PR. The effects of Escherichia coli capsule, O-antigen, host neutrophils, and complement in a rat model of Gram-negative pneumonia.. FEMS Microbiol Lett. 2003; 226(2).
Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem.. Microbes Infect. 2003; 5(5).
Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Barnard TJ, Johnson JR. IroN functions as a siderophore receptor and is a urovirulence factor in an extraintestinal pathogenic isolate of Escherichia coli.. Infect Immun. 2002; 70(12).
Johnson JR, Russo TA. Uropathogenic Escherichia coli as agents of diverse non-urinary tract extraintestinal infections.. J Infect Dis. 2002; 186(6).
Russo TA, Bartholomew LA, Davidson BA, Helinski JD, Carlino UB, Knight PR, Beers MF, Atochina EN, Notter RH, Holm BA. Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia.. Am J Physiol Lung Cell Mol Physiol. 2002; 283(3).
Johnson JR, Russo TA. Extraintestinal pathogenic Escherichia coli: 'the other bad E coli'.. J Lab Clin Med. 2002; 139(3).
Russo TA, Carlino UB, Johnson JR. Identification of a new iron-regulated virulence gene, ireA, in an extraintestinal pathogenic isolate of Escherichia coli.. Infect Immun. 2001; 69(10).
Johnson JR, O'Bryan TT, Delavari P, Kuskowski M, Stapleton A, Carlino U, Russo TA. Clonal relationships and extended virulence genotypes among Escherichia coli isolates from women with a first or recurrent episode of cystitis.. J Infect Dis. 2001; 183(10).
Johnson JR, Delavari P, Stell AL, Whittam TS, Carlino U, Russo TA. Molecular comparison of extraintestinal Escherichia coli isolates of the same electrophoretic lineages from humans and domestic animals.. J Infect Dis. 2001; 183(1).
Johnson JR, O'Bryan TT, Low DA, Ling G, Delavari P, Fasching C, Russo TA, Carlino U, Stell AL. Evidence of commonality between canine and human extraintestinal pathogenic Escherichia coli strains that express papG allele III.. Infect Immun. 2000; 68(6).
Johnson JR, Russo TA, Tarr PI, Carlino U, Bilge SS, Vary JC, Stell AL. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN(E. coli), among Escherichia coli isolates from patients with urosepsis.. Infect Immun. 2000; 68(5).
Russo TA, Davidson BA, Priore RL, Carlino UB, Helinski JD, Knight PR. Capsular polysaccharide and O-specific antigen divergently modulate pulmonary neutrophil influx in an Escherichia coli model of gram-negative pneumonitis in rats.. Infect Immun. 2000; 68(5).
Russo TA, Johnson JR. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC.. J Infect Dis. 2000; 181(5).
Johnson JR, Stell AL, Scheutz F, O'Bryan TT, Russo TA, Carlino UB, Fasching C, Kavle J, Van Dijk L, Gaastra W. Analysis of the F antigen-specific papA alleles of extraintestinal pathogenic Escherichia coli using a novel multiplex PCR-based assay.. Infect Immun. 2000; 68(3).
Russo TA, Carlino UB, Mong A, Jodush ST. Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine.. Infect Immun. 1999; 67(10).
Luke NR, Thomas Russo, Luther N, Anthony Campagnari. Use of an isogenic mutant constructed in Moraxella catarrhalis To identify a protective epitope of outer membrane protein B1 defined by monoclonal antibody 11C6.. Infect Immun. 1999; 67(2).
Russo TA, Mylotte D. Expression of the K54 and O4 specific antigen has opposite effects on the bactericidal activity of squalamine against an extraintestinal isolate of Escherichia coli.. FEMS Microbiol Lett. 1998; 162(2).
Johnson JR, Brown JJ, Carlino UB, Russo TA. Colonization with and acquisition of uropathogenic Escherichia coli as revealed by polymerase chain reaction-based detection.. J Infect Dis. 1998; 177(4).
Johnson JR, Russo TA, Brown JJ, Stapleton A. papG alleles of Escherichia coli strains causing first-episode or recurrent acute cystitis in adult women.. J Infect Dis. 1998; 177(1).
Russo TA, Wenderoth S, Carlino UB, Merrick JM, Lesse AJ. Identification, genomic organization, and analysis of the group III capsular polysaccharide genes kpsD, kpsM, kpsT, and kpsE from an extraintestinal isolate of Escherichia coli (CP9, O4/K54/H5).. J Bacteriol. 1998; 180(2).
Wang Y, Russo TA, Kwon O, Chanock S, Rumsey SC, Levine M. Ascorbate recycling in human neutrophils: induction by bacteria.. Proc Natl Acad Sci U S A. 1997; 94(25).
Johnson JR, Stapleton AE, Russo TA, Scheutz F, Brown JJ, Maslow JN. Characteristics and prevalence within serogroup O4 of a J96-like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papG.. Infect Immun. 1997; 65(6).
Johnson JR, Russo TA, Scheutz F, Brown JJ, Zhang L, Palin K, Rode C, Bloch C, Marrs CF, Foxman B. Discovery of disseminated J96-like strains of uropathogenic Escherichia coli O4:H5 containing genes for both PapG(J96) (class I) and PrsG(J96) (class III) Gal(alpha1-4)Gal-binding adhesins.. J Infect Dis. 1997; 175(4).
Russo TA, Jodush ST, Brown JJ, Johnson JR. Identification of two previously unrecognized genes (guaA and argC) important for uropathogenesis.. Mol Microbiol. 1996; 22(2).
Russo TA, Stapleton A, Wenderoth S, Hooton TM, Stamm WE. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women.. J Infect Dis. 1995; 172(2).
Russo TA, Sharma G, Weiss J, Brown C. The construction and characterization of colanic acid deficient mutants in an extraintestinal isolate of Escherichia coli (O4/K54/H5).. Microb Pathog. 1995; 18(4).
Thomas Russo, Sharma G, Brown CR, Anthony Campagnari. Loss of the O4 antigen moiety from the lipopolysaccharide of an extraintestinal isolate of Escherichia coli has only minor effects on serum sensitivity and virulence in vivo.. Infect Immun. 1995; 63(4).
Russo TA, Liang Y, Cross AS. The presence of K54 capsular polysaccharide increases the pathogenicity of Escherichia coli in vivo.. J Infect Dis. 1994; 169(1).
Russo TA, Singh G. An extraintestinal, pathogenic isolate of Escherichia coli (O4/K54/H5) can produce a group 1 capsule which is divergently regulated from its constitutively produced group 2, K54 capsular polysaccharide.. J Bacteriol. 1993; 175(23).
Godoy VG, Dallas MM, Russo TA, Malamy MH. A role for Bacteroides fragilis neuraminidase in bacterial growth in two model systems.. Infect Immun. 1993; 61(10).
Russo TA, Moffitt MC, Hammer CH, Frank MM. TnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity.. Infect Immun. 1993; 61(8).
Russo TA, Guenther JE, Wenderoth S, Frank MM. Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption.. Mol Microbiol. 1993; 9(2).
Russo TA, Thompson JS, Godoy VG, Malamy MH. Cloning and expression of the Bacteroides fragilis TAL2480 neuraminidase gene, nanH, in Escherichia coli.. J Bacteriol. 1990; 172(5).
Russo TA, Cook S, Gorbach SL. Intramuscular ceftriaxone in home parenteral therapy.. Antimicrob Agents Chemother. 1988; 32(9).
Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB School of Medicine and Biomedical Sciences.